Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pathology

Decoding Your Pathology: Subtypes and Markers

At a Glance

Differentiated thyroid carcinoma (DTC) pathology reports detail your tumor's specific subtype, genetic mutations, and microscopic characteristics. Key details like tumor size, margin status, and molecular markers like BRAF or TERT help your medical team determine the most effective treatment plan.

Your pathology report is the definitive “map” of your diagnosis. It is a technical document written by a pathologist—a doctor who studies tissues—after examining your thyroid tissue under a microscope. Understanding this report is one of the most empowering steps you can take in your care.

The Major Subtypes of DTC

Differentiated Thyroid Carcinoma (DTC) is not one single disease; it is a category of cancers that still resemble healthy thyroid cells [1]. The 2022 World Health Organization (WHO) update refined how these are classified to ensure more accurate treatment [2]:

  • Papillary Thyroid Carcinoma (PTC): The most common subtype. It typically grows slowly and often spreads to lymph nodes in the neck, but it has a very high cure rate [3][2].
  • Follicular Thyroid Carcinoma (FTC): The second most common type. It is more likely than PTC to spread through the bloodstream to other parts of the body [1].
  • Oncocytic Carcinoma (formerly Hürthle Cell): Previously considered a variant of FTC, the 2022 WHO guidelines now recognize this as a distinct type [4]. These tumors are composed of at least 75% oncocytes (large, granular cells) and may be less responsive to radioactive iodine treatment [5][6].

When Cancer “Isn’t” Cancer: The NIFTP Reclassification

One of the most important changes in thyroid pathology was the creation of the NIFTP category (Non-invasive Follicular Thyroid Neoplasm with Papillary-like nuclear features) [7].

In the past, these tumors were called “cancer.” However, because they are encapsulated (contained in a “sac”) and do not invade surrounding tissue, they are now classified as non-malignant [8][9]. If your report says NIFTP, it means your tumor is considered low-risk and may not require the aggressive treatments (like radioactive iodine) used for true carcinomas [10][7].

Important Note: Even though NIFTP is not considered malignant, surgery (usually a partial removal, or lobectomy) is still required to officially diagnose it. This is because a pathologist must examine the entire tumor capsule under a microscope to guarantee the abnormal cells have not invaded the surrounding tissue.

Demystifying Molecular Markers

Your doctor may order molecular testing to look for specific genetic changes (“mutations”) in the tumor cells. This helps predict how the cancer might behave:

  • BRAF V600E: Found in about 60% of PTC cases [3]. While common, it can sometimes be associated with more aggressive features like spread to lymph nodes [11].
  • RAS: These mutations are common in follicular-patterned tumors, including FTC and NIFTP [12].
  • TERT Promoter: This is a “red flag” marker. If a tumor has a TERT mutation—especially alongside a BRAF mutation—it may be more aggressive and require more intensive monitoring [13][14].
  • RET/PTC or NTRK Fusions: These are “driver” mutations that can sometimes be targeted with specific modern drugs if the cancer is advanced [15][16].

Your Pathology Completeness Checklist

A complete pathology report is essential for accurate staging. Ensure your report includes these specific data points:

Element Why It Matters
Tumor Size The largest dimension of the tumor in centimeters [17].
Histologic Type The specific subtype (e.g., Papillary, Follicular, Oncocytic) [2].
Variants Noted if aggressive variants like “Tall Cell” or “Hobnail” are present [18].
Margins Whether the edges of the removed tissue are clear of cancer cells [19].
Extrathyroidal Extension (ETE) Whether the cancer has grown outside the thyroid gland into nearby tissue [3].
Angioinvasion Whether cancer cells have invaded blood vessels (critical for FTC) [20].
Lymph Nodes The number of nodes removed and how many contained cancer [21].

If any of these items are missing, you can ask your endocrinologist or surgeon if an addendum or a second review of the pathology is needed.

Common questions in this guide

What is NIFTP on a thyroid pathology report?
NIFTP stands for Non-invasive Follicular Thyroid Neoplasm with Papillary-like nuclear features. It is a contained, low-risk tumor that was previously considered cancer but is now classified as non-malignant because it does not invade surrounding tissue.
What does a BRAF V600E mutation mean for thyroid cancer?
The BRAF V600E mutation is a genetic change found in about 60% of papillary thyroid carcinoma cases. While very common, it can sometimes indicate that the tumor has a higher chance of spreading to nearby lymph nodes.
Why is a TERT promoter mutation considered a red flag?
A TERT mutation, especially when found alongside a BRAF mutation, suggests the tumor may behave more aggressively. Patients with this specific genetic marker typically require closer monitoring and potentially more intensive treatment.
What does angioinvasion mean on my pathology report?
Angioinvasion means that cancer cells have broken through and invaded the blood vessels within the thyroid tissue. This is a critical detail, particularly for follicular thyroid carcinoma, as it helps doctors predict how the cancer might spread.
What are aggressive variants in thyroid cancer?
Terms like "Tall Cell" or "Hobnail" describe specific microscopic patterns of thyroid cancer cells. When these variants are noted on your report, it indicates a subtype that may behave more aggressively than standard papillary thyroid cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report show any aggressive variants, such as the Tall Cell or Hobnail variants?
  2. 2.Was my tumor tested for the TERT promoter mutation? If not, do you recommend it for better risk assessment?
  3. 3.What was the status of my margins? Were they positive, negative, or close (less than 1mm)?
  4. 4.Is there any evidence of angioinvasion (cancer cells in the blood vessels), and how many vessels were involved?
  5. 5.Given the 2022 WHO classification, how does the specific subtype of my cancer affect my follow-up schedule?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.

    Moon S, Song YS, Jung KY, et al.

    Endocrinology and metabolism (Seoul, Korea) 2025; (40(3)):357-384 doi:10.3803/EnM.2025.2465.

    PMID: 40598904
  2. 2

    SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

    Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, et al.

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(2)):100859 doi:10.1016/j.patol.2026.100859.

    PMID: 41747300
  3. 3

    Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality.

    Gatta E, Pirola I, Gandossi E, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):416-426 doi:10.1016/j.eprac.2025.12.003.

    PMID: 41419184
  4. 4

    WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm.

    Goswami P, Patel T, Dave R, et al.

    Journal of medicine and life 2024; (17(1)):15-23 doi:10.25122/jml-2023-0270.

    PMID: 38737660
  5. 5

    Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.

    Bischoff LA, Ganly I, Fugazzola L, et al.

    JAMA otolaryngology-- head & neck surgery 2024; (150(3)):265-272 doi:10.1001/jamaoto.2023.4323.

    PMID: 38206595
  6. 6

    Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

    Janovitz T, Barletta JA

    Endocrine pathology 2018; (29(4)):357-364 doi:10.1007/s12022-018-9548-1.

    PMID: 30238434
  7. 7

    Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment.

    Thompson LD

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(7)):698-707 doi:10.1038/modpathol.2016.65.

    PMID: 27102347
  8. 8

    [Diagnostic principles of thyroid tumors in pathology : Relevant changes due to the current WHO classification].

    Theurer S, Rawitzer J, Ting S, Schmid KW

    Der Pathologe 2021; (42(1)):125-139 doi:10.1007/s00292-020-00908-3.

    PMID: 33415346
  9. 9

    Thyroid tumors with follicular architecture.

    Turk AT, Wenig BM

    Annals of diagnostic pathology 2019; (38()):51-58 doi:10.1016/j.anndiagpath.2018.10.007.

    PMID: 30419427
  10. 10

    Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features is Rare: A Population Based Study of Incidence.

    Reinke RH, Larsen SR, Mathiesen JS, et al.

    Head and neck pathology 2020; (14(1)):144-149 doi:10.1007/s12105-019-01032-2.

    PMID: 30900211
  11. 11

    BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.

    Al-Salam S, Sharma C, Afandi B, et al.

    PloS one 2020; (15(4)):e0231341 doi:10.1371/journal.pone.0231341.

    PMID: 32315324
  12. 12

    Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.

    Soares P, Póvoa AA, Melo M, et al.

    Endocrine pathology 2021; (32(1)):44-62 doi:10.1007/s12022-021-09666-1.

    PMID: 33651322
  13. 13

    A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma.

    Vuong HG, Duong UN, Altibi AM, et al.

    Endocrine connections 2017; (6(3)):R8-R17 doi:10.1530/EC-17-0010.

    PMID: 28219937
  14. 14

    Genetic-guided Risk Assessment and Management of Thyroid Cancer.

    Xing M

    Endocrinology and metabolism clinics of North America 2019; (48(1)):109-124 doi:10.1016/j.ecl.2018.11.007.

    PMID: 30717896
  15. 15

    Application value of multi-gene mutation detection in the clinical management of pediatric papillary thyroid carcinoma: a preliminary exploration.

    Wang Y, Wang H, Tan G, et al.

    Frontiers in endocrinology 2024; (15()):1405142 doi:10.3389/fendo.2024.1405142.

    PMID: 38904052
  16. 16

    Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis.

    Lan X, Bao H, Ge X, et al.

    Cancer science 2020; (111(6)):2163-2173 doi:10.1111/cas.14389.

    PMID: 32187423
  17. 17

    Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.

    Kim K, Kim JK, Lee CR, et al.

    Therapeutic advances in endocrinology and metabolism 2020; (11()):2042018820921019 doi:10.1177/2042018820921019.

    PMID: 32489582
  18. 18

    The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes.

    Watutantrige-Fernando S, Vianello F, Barollo S, et al.

    Thyroid : official journal of the American Thyroid Association 2018; (28(1)):96-103 doi:10.1089/thy.2017.0248.

    PMID: 29179638
  19. 19

    Impact of microscopic margin involvement on recurrence of papillary thyroid carcinoma.

    Kwon H, Kim H, Hwang H, Moon BI

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025; (51(9)):110208 doi:10.1016/j.ejso.2025.110208.

    PMID: 40466404
  20. 20

    The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology.

    Rossi ED, Baloch Z

    Endocrine pathology 2023; (34(1)):23-33 doi:10.1007/s12022-023-09756-2.

    PMID: 36797454
  21. 21

    Pure red-cell aplasia after radioactive iodine treatment in a patient with papillary thyroid cancer and follow up for two years: a case report.

    Li R, Wang M, Li S, Liao L

    Frontiers in oncology 2025; (15()):1539586 doi:10.3389/fonc.2025.1539586.

    PMID: 40630205

This page explains differentiated thyroid carcinoma pathology terminology for educational purposes only. Your pathologist and endocrinologist are the best sources for interpreting your specific pathology report.

Get notified when new evidence is published on Differentiated thyroid carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.